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Efficacy and Safety of Artemether-Lumefantrine in the Treatment of Acute, Uncomplicated
Plasmodium falciparum Malaria: A Pooled Analysis
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Abstract. Randomized trials have confirmed the efficacy and safety of artemether-lumefantrine (AL) for treatment
of uncomplicated Plasmodium falciparum malaria. Data from seven studies supported by Novartis (1996–2007), including 647 adults (> 16 years of age, 83.3% completed the study) and 1,332 children (≤ 16 years of age, 89.3% completed the
study) with microscopically confirmed uncomplicated P. falciparum malaria and treated with the recommended regimen
of AL, were pooled. The 28-day polymerase chain reaction–corrected parasitologic cure rate (primary efficacy endpoint)
was 97.1% (495 of 510) in adults and 97.3% (792 of 814) in children (evaluable population). Gametocytemia prevalence
after day was 4.2% (23 of 554) in adults and 0.9% (8 of 846) in children. No noteworthy safety signals were observed.
Serious adverse events occurred in 1.4% of the adults and 1.3% of the children. This study is the largest data set to date
assessing AL therapy for treatment of acute uncomplicated P. falciparum malaria. Artemether-lumefantrine showed high
cure rates and rapid resolution of parasitemia, fever, and gametocytemia in adults and children, and showed an excellent
safety and tolerability profile.

for adults and children because of differences between these
groups in antimalarial immunity,29,30 transmission intensity,
and disposition of some antimalarial drugs.31
A recent Cochrane analysis evaluated the efficacy of ACTs
for the treatment of uncomplicated P. falciparum malaria
and confirmed that the polymerase chain reaction (PCR)–
corrected parasitologic cure rate for AL at day 28 was > 95%
in all the trials reviewed.2 However, this analysis did not assess
efficacy or safety outcomes separately among adults, children,
or other subpopulations. Two pooled analyses of outcomes
with AL have been performed in which children and adults
were studied and the populations were defined by age,18,32
but the cut-off point used (12 years) is not the one recommended by the U.S. Food and Drug Administration (FDA)
(i.e., 16 years).6
We report efficacy and safety findings for AL in a post-hoc
pooled analysis of data from the Novartis study database, which
includes approximately 2,000 children and adults treated for
uncomplicated P. falciparum malaria during 1996–2007. The
analysis population was derived from six studies undertaken
in Asia and Africa and one study in patients from Europe and
Colombia. This, it encompasses regions with varying endemicity and transmission patterns.

INTRODUCTION
The World Health Organization (WHO) recommends that
artemisinin-based combination therapies (ACTs) be used as
first-line treatment of uncomplicated Plasmodium falciparum
malaria.1 Treatment with ACTs is currently considered more
effective than available non-artemisinin regimens,2 resulting
in faster symptomatic improvement and parasite clearance1,3
and a reduction in gametocyte carriage, which could help to
reduce malaria transmission.1,4–6
In 2004, artemether-lumefantrine (AL, Coartem®, Novartis
Pharma AG, Basel, Switzerland) became the first ACT to be
pre-qualified by WHO, and it is now used as first-line treatment for uncomplicated Plasmodium falciparum malaria in
many regions worldwide.7 The combination of artemether,
which rapidly reduces parasite biomass,8 with longer-acting
lumefantrine, capable of eliminating residual parasites,9 has
proven to be highly effective in achieving parasitologic cure,
symptom relief,10–15 and reduction of gametocyte carriage.15,16
Typically, although with uncommon exceptions,17 the 28-day
parasitologic cure observed after AL therapy exceeded 95%
in evaluable patients,10–15,18–20 meeting the WHO recommendation that cure rates for P. falciparum malaria should be at least
90% and preferably > 95%.1
Although numerous randomized, controlled trials have confirmed the efficacy and safety of AL for treatment of uncomplicated P. falciparum malaria in regions worldwide,10–14,20–28
further analyses are desirable to ascertain whether efficacy
is affected by different patient characteristics and to identify
any infrequent safety concerns not detected within the limited
sizes of individual trials. It is useful to examine data separately

MATERIALS AND METHODS
Study identification and design. Data from clinical trials
within the Novartis database were included in this unplanned
pooled analysis if they enrolled patients treated with the
recommended regimen of AL, administered twice a day for
three days, and diagnosis of P. falciparum malaria was based
on microscopically confirmed evaluation of Giemsa-stained
blood slides. Patients with severe or complicated malaria were
not included in this analysis. Study B2303 used an investigatorblinded design and A025 used a double-blind design; the
remaining studies were open label. Six of the studies were
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performed in malaria-endemic countries (studies A025,
A026, A028, and A2412 in Thailand; A2403 and B2303 in
Africa)19,26,27,33–35 and one involved non-immune adult travelers
in Europe and non-endemic regions of Colombia (A2401).36
The B2303 study was a randomized trial of the AL dispersible
formulation versus AL tablets administered crushed: patients
receiving the dispersible tablet were only included in the safety
analyses (data from the B2303 study population confirmed
equivalent efficacy and safety of the dispersible formulation
and the crushed AL tablets).34 The A2401 study included
only adults. Studies A2403 and B2303 included only children
(< 10 years of age and ≤ 12 years of age, respectively), and
were both conducted in Africa (A2403: Kenya, Nigeria,
and Tanzania; B2303: Benin, Kenya, Mali, Mozambique,
and Tanzania). Three of the trials (A025, A026, and A028)
took places during 1996–1999, and four took place during
2001–2007 (A2401, A2403, B2303, and A2412).
In all studies, AL dosing was based on body weight:
5–< 15 kg, 1 tablet per dose; 15–< 25 kg, 2 tablets per dose;
25–< 35 kg, 3 tablets per dose; ≥ 35 kg, 4 tablets per dose.
Patients who vomited the first dose within one hour of treatment received a full replacement in all studies. The protocols
of A2403 and B2303 specified that no more than two doses
were to be replaced during the entire treatment period.
Six of the studies (A025, A026, A028, A2403, B2303, and
A2401) recorded the 28-day parasitologic cure rate, corrected
for re-infection by PCR in studies A025, A026, A028, A2403,
and B2303 (as defined below under Data analysis), consistent with draft guidance from the FDA. The PCR analysis was
performed by analysis of size polymorphisms in the P. falciparum genes encoding merozoite surface protein 2, merozoite surface protein 1, and glutamate-rich protein37,38 in studies
A025, A026, A028, A2403, and B2303. The PCR analysis was
not performed in study A2401 because the patients were travelers from regions to which malaria was not endemic and who
were not at risk of a new infection. In this study, any recurring parasites were regarded as recrudescences. These studies
also recorded time to parasite and fever clearance, as defined
below (see Data analysis). The remaining study (A2412) was
an open-label, single-center, safety study and was included
only in the safety analysis. Patients were followed-up for at
least 28 days in all studies. Giemsa-stained thick blood smears
were examined for asexual forms and gametocytes on days
0–7 (day 0, first day of AL treatment) and thereafter on days
14, 21, 28, and 42. All doses of AL were given under supervision in all studies except A2401.
Data analysis. The main efficacy variable was the 28-day
PCR-corrected parasitologic cure rate, which was defined as
the proportion of patients with clearance of asexual parasitemia
within 7 days of the first dose of AL and without subsequent
recrudescence within 28 days. Recrudescence was defined as
reappearance of the original parasite strain as confirmed by
PCR-based genotyping. Other efficacy endpoints were the
28-day non–PCR-corrected parasitologic cure rate, time to
parasite clearance, time to fever clearance, and proportion of
patients with gametocytes at specific time points. The times at
which patients were assessed for parasite clearance and fever
clearance varied between studies. The presence of gametocytes
was recorded at baseline, > 0–72 hours, > 72 hours–day 7, and
> day 7.
Safety data included the incidence, type, and study drug
relationship of adverse events. Adverse events were defined

as the appearance or worsening of any undesirable sign, symptom, or medical condition after starting the study drug, even if
the event was not considered to be related to the study drug,
according to the International Conference on Harmonization
Guidelines. A serious adverse event was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of
existing hospitalization, resulted in persistent or significant
disability/incapacity, or was a congenital anomaly/birth defect.
Other safety data included the incidence of death and serious
adverse events, clinical laboratory assessments, and vital signs.
The availability of laboratory data varied between studies in
terms of parameters measured and time of sample collection.
Creatinine clearance was used as a measure of renal function,
and was calculated according to the Cockcroft-Gault formula
in adults39 and the Shull formula in children.40
Statistical analysis. Patients > 16 years of age were included
in the adult analysis populations; patients ≤ 16 years of age
were included in the pediatric analysis population. Efficacy
and safety data were taken from the original study databases.
Efficacy analyses were based on the modified intentto-treat (mITT) population, which was generally defined as
all patients with parasitologically confirmed P. falciparum
malaria who received at least one dose of study drug. This
definition was selected to comply with FDA draft guidance.41
Efficacy analyses were also performed for evaluable patient
populations. Definitions of the evaluable patient population
differed between studies, but in general the evaluable population included patients from the mITT population who took
no other drug that had an anti-malarial effect, and had parasite counts recorded up to day 28, or who discontinued the
study because of an unsatisfactory therapeutic effect. A post
hoc analysis of the primary efficacy endpoint, 28-day PCRcorrected parasitologic cure rate, was performed on the basis
of data only from study A2401 by using the last observation
carried forward technique.
The 28-day PCR-corrected parasitologic cure rate was also
reported for subpopulations of the evaluable population,
according to the following variables: 1) baseline parasite count
(≤ 100,000/μL or > 100,000/μL); 2) sex; 3) baseline renal function based on creatinine clearance (normal > 80 mL/min; mild
dysfunction ≥ 50–≤ 80 mL/min; moderate dysfunction ≥ 30–
< 50 mL/min; or severe dysfunction < 30 mL/min) (creatinine clearance < 30 mL/min is indicative of severe malaria in
adults and no adult patients with severe renal dysfunction were
recruited, in adherence with the studies’ exclusion criteria);
4) baseline hepatic function (normal, total bilirubin ≤ upper
limit of normal [ULN], and aspartate aminotransferase [AST]
≤ ULN if available; mild dysfunction, total bilirubin ≤ ULN and
AST > ULN, or total bilirubin > ULN – 1.5 × ULN; moderate
dysfunction, total bilirubin > 1.5 – 3 × ULN; severe dysfunction,
total bilirubin > 3 × ULN; if the AST value was missing, baseline alanine aminotransferase value was used as per the criteria
for AST); and 5) age (pediatric population only) (> 1 month–
≤ 2 years, > 2–≤ 16 years, or >12–≤ 16 years) and body weight
(5–< 10 kg, 10–< 15 kg, 15–< 25 kg, 25–< 35 kg, or ≥ 35 kg).
All data are presented descriptively. One-sample 95% confidence intervals (CIs) for the 28-day PCR-corrected cure
rate were calculated by using the Pearson-Clopper method.
Kaplan-Meier estimates of parasite clearance time and fever
clearance time were calculated. Laboratory data are presented
as standard summary statistics. Because of the variation
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between studies in the time points used for laboratory evaluations and deviations from schedules, time windows were
defined. If a patient had more than one value within a given
interval, the mean was used for summarization. Summary statistics for laboratory data should be interpreted carefully in
view of the variation between time windows and the numbers
of patients with available data. Safety analyses were based on
all randomized/enrolled patients who received at least one
dose of study drug. Statistical analyses were performed using
the SAS software system (SAS Institute, Cary, NC).
Study conduct. All studies were conducted according to the
Declaration of Helsinki, and informed consent was obtained
from all patients (or parents/guardians where appropriate)
according to appropriate institutional review board approval.
RESULTS
Populations for analysis and patient disposition. For adults,
the mITT population comprised 599 patients, of whom 437 took
part in studies from malaria-endemic regions (studies A025,
A026, and A028), and 162 were travelers from non-endemic
regions (study A2401) (Table 1). The evaluable population
comprised 513 patients. Patients who received at least one
dose of AL were considered for safety evaluation. The safety
population comprised 647 patients, including 44 from study
A2412, who were not included in the efficacy analysis because
efficacy was addressed only as secondary objective and the
study was stopped early for administrative reasons. For children
(age ≤ 16 years), the mITT population comprised 877 patients
and the evaluable population comprised 828 patients. A total
of 1,333 pediatric patients were enrolled, but one patient in
study A2412 did not receive AL and was excluded from the
safety population. In study B2303, 447 patients received
dispersible AL and were included in the safety, but not in the
efficacy analysis. For children and adults, at least 83% of the
mITT and safety populations completed the study (Figure 1).
Patient demographics and baseline disease characteristics
are shown in Table 2. Information on race was not collected
in studies A025, A026, or A028, which studied populations
in Thailand. In the pediatric population, more than 90% of
patients were ≤ 12 years of age; almost half were 1 month–2
years of age. A total of 29 children in the pediatric mITT population (3.3%), 28 patients in the pediatric evaluable population (3.4%), and 36 patients in the pediatric safety population
(2.7%) were 1–6 months of age. Approximately 90% of adults
and children for whom parasite counts were available had a
count ≤ 100,000/μL.
Exposure to AL. The full recommended regimen of AL
was taken by 96.9% of adults (n = 627) and 97.1% of children
(n = 1,332) (safety populations). Seven adults (1.1%) and 140
children (10.5%) vomited at least one dose of AL.
Parasitologic cure. Parasitologic cure rates on day 28 among
the pooled efficacy population are summarized in Table 3. In
adults, the 28-day PCR-corrected parasitologic cure rate was
97.1% (495 of 510; 95% CI = 95.2–98.3%) in the evaluable
population and 83.4% (499 of 598; 95% CI = 80.2–86.3%) in
the mITT population. The difference in results was caused
primarily by study A2401, the only study of non-immune
travelers, in which a large number of patients did not undergo
parasitologic assessments as scheduled. In this study, 33 of
the 42 patients showed treatment failure. These results were
caused by missing parasite assessments at day 28; negative

795

blood smears were available at earlier time points for 27of
these persons. An additional five treatment failures were
so-classified because the patients received other antimalarial
medications. Thus, in study A2401, the mITT cure rate was
74.1% (120 of 162; 95% CI = 66.6–80.6%), and the evaluable
cure rate was 96.0% (119 of 124; 95% CI = 90.8–98.7%); a
post hoc analysis using the last observation carried forward
technique showed a 90.7% cure rate (147 of 162).
One potential explanation for treatment failures may be
underdosing of larger patients. In the evaluable population
of study A2401, the cure rate was 93.0% (66 of 71; 95% CI =
84.3–97.7%) in patients weighing ≥ 70 kg versus 100% (52
of 52; 95% CI = 93.2–100%) in patients < 70 kg. Of the five
patients weighing ≥ 70 kg who were classified as treatment
failures, one patient discontinued treatment after the second
dose because of signs and symptoms of severe malaria that
were already present at baseline, one missed an assessment at
day 6 but was clear of parasites at day 7, and three had recrudescence during days 21 and 28. In addition, of four patients
with body weights >100 kg, three were clear of parasites at day
28, and one did not have a day 28 blood assessment, but was
parasite free at 58 and 154 hours.
In the pediatric population, the 28-day PCR-corrected parasitologic cure rate was 97.3% (792 of 814; 95% CI = 95.9–
98.3%) in the evaluable population and 93.4% (798 of 854;
95% CI = 91.6–95.0%) in the mITT population. No differences were observed between age groups or different body
weight categories, including patients ≤ 2 years of age or those
weighing < 10 kg (Table 4).
Baseline parasite density did not appear to affect the 28-day
PCR-corrected cure rate in either adults or children (Table 4).
There was a trend towards a lower cure rate in patients with
impaired hepatic function in the adult and pediatric populations, but there were few patients with moderate/severe impairment (only 13 adults and 2 children with severe impairment),
which limited the reliability of these findings (Table 4).
Parasite clearance time. The median time to parasite
clearance was 42.3 hours (95% CI = 41.5–43.2 hours) in the
adult mITT population, and parasite clearance was achieved
within 48 hours in 78.6% of patients (Table 5). For children,
the median parasite clearance time for the mITT population
was 35.3 hours (95% CI = 31.7–35.7 hours), and 90.3% of
patients showed parasite clearance in ≤ 48 hours. In the study
A2401 mITT analysis, the median time to parasite clearance
was 41.8 hours (95% CI = 40.3–43.8 hours), and 108 (066.7%)
of 162 patients showed parasite clearance ≤ 48 hours.
Fever clearance time. In adults, the median time to fever
clearance was 28.5 hours (95% CI = 22.3–34.0 hours). Median
time to fever clearance was shorter in patients with a baseline
parasite count ≤ 100,000/μL (n = 464, 22.1 hours; 95% CI =
21.2–24.0 hours) compared with those with a baseline count
> 100,000/μL (n = 34, 43.1 hours; 95% CI = 21.7–45.9 hours).
The median fever clearance time in children (7.9 hours; 95%
CI = 7.9–8.0 hours) was markedly shorter than that in adults
(28.5 hours; 95% CI = 22.3–34.0 hours). As in adults, a low
baseline P. falciparum count (≤ 100,000/μL) was associated
with slightly shorter fever clearance time (n = 788, 7.9 hours;
95% CI = 7.8–8.0 hours) compared with those with parasite
counts > 100,000/μL (n = 88, median 11.3 hours; 95% CI =
7.9–23.4 hours). For study A2401, the median time to fever
clearance among patients with fever at baseline was 36.5 hours
(95% CI = 27.8–39.5 hours in the mITT population).
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Characteristics of studies included in pooled analysis for patients treated for uncomplicated Plasmodium falciparum malaria*
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Figure 1. Patient disposition for adults and children in the study of artemether-lumefantrine for treatment of uncomplicated Plasmodium
falciparum malaria.

Gametocyte carriage. The proportion of adult patients with
P. falciparum gametocytes at baseline was 9.7% (58 of 596),
which decreased to 4.2% (23 of 554) after day 7 (Table 5).
Among children, 45 (5.1%) of 877 patients had gametocytes
at baseline and 8 (0.9%) of 846 patients had gametocytes
after day 7. For study A2401, 11.9% (19 of 160) and 1.4% (2
of 139) of patients had gametocytes at baseline and after day
7, respectively. Primaquine, which has gametocytocidal activity
and could be prescribed at the discretion of the investigator,42
was administered to less than 1% of the patients, mostly after
day 7 to treat concomitant P. vivax infections or to eliminate
P. falciparum gametocytes.
Adverse events in adults. One or more adverse events
were reported by 557 (86.1%) of 647 adult patients. The
most frequently reported adverse events were non-specific
(headache, anorexia, dizziness, asthenia, arthralgia, myalgia,
and nausea) and consistent with symptoms of acute malaria
(Table 6). Adverse events potentially related to hypersensitivity
reactions were reported by 4.0% of adults (rash = 3.2%,
urticaria = 0.6%, facial edema = 0.2%). These adults showed an

incidence of 2.8% during days 0–3 of treatment and 1.0% during
days 4–10 of treatment (Table 7). Nervous system disorders,
mainly headache (55.6%) and dizziness (39.1%), occurred in
59.7% of adults. These results are also consistent with malaria
symptoms. Ear and labyrinth disorders were reported for 29
patients (4.5%), of whom 21 experienced vertigo. Prolonged
QT interval on electrocardiogram was reported for two
adult patients (0.3%); however, syncope, sudden cardiac
death, seizure, or significant ventricular arrhythmias was not
reported for these patients. One adult patient (1 of 647, 0.2%)
stopped treatment prematurely because of adverse events
(mild abdominal pain/diarrhea).
No adult patient died. Nine patients (1.4%) experienced
22 serious adverse events. No type of serious adverse event
occurred in more than one patient except for P. falciparum
infection, which was reported by investigators as a serious
adverse event in two patients. Of the 22 serious adverse events,
18 occurred in study A2401, in which prolongation of hospitalization required a classification of serious adverse event. There
were no cases of urticaria or anaphylactoid reaction reported

798

MAKANGA AND OTHERS

Table 2
Demographics and baseline disease characteristics of the study populations for patients treated with artemether-lumefantrine for uncomplicated
Plasmodium falciparum malaria*
Adults
Characteristic

Efficacy mITT population (n = 599)

Male sex, no. (%)
434 (72.5)
Age (years)
Mean ± SD
31.2 ± 11.5
Range
17–71‡
> 0 to ≤ 2, no. (%)
–
> 2 to ≤ 12, no. (%)
–
> 12 to ≤ 16, no. (%)
–
Race, no. (%)
Caucasian
77 (12.9)
Black
40 (6.7)
Asian
0
Other
45 (7.5)
Not collected
437 (73.0)
Body weight (kg)
Mean ± SD
57.4 ± 13.4¶
Range
34–119¶
5–< 10, no. (%)
–
10–< 15, no. (%)
–
15–< 25, no. (%)
–
25–< 35, no. (%)
–
≥ 35, no. (%)
–
P. falciparum parasite count (asexual forms/μL)
Median
4,618
Range
13–464,880
≤ 100,000, no. (%)
464 (77.5)
<2,000, no. (%)
163 (27.2)
2,000–< 5,000
90 (15.0)
5,000–< 15,000
66 (11.0)
15,000–< 50,000
98 (16.4)
50,000–< 100,000
47 (7.8)
> 100,000, no. (%)
34 (5.7)
None, no. (%)
0
Missing/different unit, no. (%)
101 (16.9)
Body temperature (°C)
Mean ± SD
37.9 ± 1.1
< 37.5, no. (%)
235 (39.2)
37.5–< 39.0, no. (%)
243 (40.6)
≥ 39.0, no. (%)
121 (20.2)
Missing, no. (%)
0
Renal function at baseline**
Normal, no. (%)
223 (37.2)
Mild dysfunction, no. (%)
143 (23.9)
Moderate dysfunction, no. (%)
9 (1.5)
Severe dysfunction, no. (%)
0 (0)
Missing, no. (%)
224 (37.4)
Hepatic function at baseline‡‡
Normal, no. (%)
164 (27.4)
Mild dysfunction, no. (%)
121 (20.2)
Moderate dysfunction, no. (%)
60 (10.0)
Severe dysfunction, no. (%)
17 (2.8)
Missing, no. (%)
237 (39.6)

Children
Safety population (n = 647)

Efficacy mITT population (n = 877)

Enrolled population (n = 1,333†)

472 (73.0)

476 (54.3)

711 (53.3%)

31.0 ± 11.4
17–71§
–
–
–

4.2 ± 4.1
0–16
410 (46.8)
410 (46.8)
57 (6.5)

4.1 ± 3.7
0–16
587 (44.0)
680 (51.0)
66 (5.0)

80 (12.4)
40 (6.2)
44 (6.8)
45 (7.0)
438 (67.7)

0
762 (86.9)
0
0
115 (13.1)

0
1,209 (90.7)
9 (0.7)
0
115 (8.6)

57.0 ± 13.2
34–119#
–
–
–
–
–

15.6 ± 9.1
5.0–58.0
238 (27.1)
309 (35.2)
217 (24.7)
57 (6.5)
56 (6.4)

15.3 ± 8.4
5.0–58.0
323 (24.2)
498 (37.4)
361 (27.1)
87 (6.5)
64 (4.8)

23,762
188–628,571
786 (89.6)
44 (5.0)
112 (12.8)
194 (22.1)
262 (29.9)
174 (19.8)
91 (10.4)
0
0

24,178
0–628,571
1,183 (88.7)
50 (3.8)
165 (12.4)
276 (20.7)
440 (33.0)
252 (18.9)
147 (11.0)
1 (0.1)
2 (0.2)

37.8 ± 1.1
267 (41.3)
255 (39.4)
125 (19.3)
0

38.2 ± 1.0
164 (18.7)
485 (55.3)
227 (25.9)
1 (0.1)

38.2 ± 1.1
301 (22.6)
709 (53.2)
319 (23.9)
4 (0.3)

225 (34.8)
143 (22.1)
10 (1.5)
0 (0)
269 (41.6)

184 (21.5)
321 (36.6)
191 (21.8)
92 (10.5)
89 (10.1)

326 (24.5)††
510 (38.3)††
292 (21.9)††
102 (7.7)††
102 (7.7)††

167 (25.8)
121 (18.7)
60 (9.3)
17 (2.6)
282 (43.6)

144 (16.4)
170 (19.4)
24 (2.7)
2 (0.2)
537 (61.2)

144 (10.8)
170 (12.8)
24 (1.8)
2 (0.2)
992 (74.5)

5,236
0–464,880
505 (78.1)
176 (27.2)
92 (14.2)
92 (14.2)
110 (17.0)
51 (7.9)
37 (5.7)
4 (0.6)
101 (15.6)

* mITT = modified intent-to-treat.
† One patient in study B2412 did not receive artemether-lumefantrine and was excluded from the safety population.
‡ Three patients were ≥ 65 years of age.
§ Two patients were ≥ 65 years of age.
¶ Study A2401: mean ± SD = 72.9 ± 13.5 kg, range 47–119 kg (66 patients weighed > 70 kg and 5 patients weighed > 100 kg).
# One patient weighed < 35 kg.
** Defined by creatinine clearance (Cockcroft-Gault/Shull): normal > 80 mL/minute; mild dysfunction ≥ 50–≤ 80 mL/minute; moderate dysfunction ≥ 30–< 50 mL/minute; or severe dysfunction
< 30 mL/minute.
†† Safety population (n = 1,332).
‡‡ Defined as normal, either total bilirubin ≤ upper limit of normal [ULN], and aspartate aminotransferase [AST] ≤ ULN or total bilirubin ≤ ULN and AST value missing; mild dysfunction, either
total bilirubin ≤ ULN and AST> ULN, or total bilirubin > ULN – 1.5 × ULN regardless of AST value; moderate dysfunction, total bilirubin > 1.5 – 3 × ULN regardless of AST value; severe dysfunction, total bilirubin > 3 × ULN regardless of AST value; missing, baseline for total bilirubin is missing regardless of whether AST value is missing. If baseline AST value was missing, baseline alanine
aminotransferase value was used as per the criteria for AST.

as serious adverse events. Seven serious adverse events in three
patients had a suspected relation to AL (abnormal liver function test results in one patient; disease progression/increased
bilirubin/increased transaminases/mental impairment/vomiting in one patient; and recrudescence in one patient). An
additional 13 serious adverse events were not suspected to be

related to AL, and the relationship with AL was unknown for
the final two events.
The overall incidence of adverse events in patients with
normal renal function or mild impairment was 77.8% (175
of 225) and 78.3% (112 of 143), respectively. The small number of patients with moderate renal impairment (n = 10) each
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Table 3
Parasitologic cure rate at day 28 for patients treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria*
Adults (all patients)
Group

mITT population
Non-PCR corrected
PCR corrected†
Evaluable patients
Non-PCR corrected
PCR corrected†

No./total (%)

Adults (Study A2401)

Children

95% CI

No./total (%)

95% CI

No./total (%)

95% CI

497/599 (83.0)
499/598 (83.4)

79.7–85.9
80.2–86.3

120/162 (74.1)
120/162 (74.1)‡

66.6–80.6
66.6–80.6

743/863 (86.1)
798/854 (93.4)

83.6–88.3
91.6–95.0

494/511‡ (96.7)
495/510§¶ (97.1)

94.7–98.1
95.2–98.3

119/124 (96.0)
119/124 (96.0)

90.8–98.7
90.8–98.7

737/823 (89.6)
792/814 (97.3)

87.3–91.6
95.9–98.3

* CI = confidence interval; mITT = modified intent-to-treat; PCR = polymerase chain reaction.
† PCR analysis was not performed in study A2401.
‡ Two patients were excluded from this analysis after starting antimalarial treatments before day 28 (for reasons other than rescue medication).
§ Last observation carried forward: 147 of 162 (90.7%).
¶ One patient was excluded because of a new infection that started before day 28.

reported one or more adverse events. Subgroup analysis by
hepatic function at baseline showed that the incidence of
adverse events in adult patients with normal hepatic function
or mild, moderate, or severe hepatic impairment at baseline
was 71.9% (120 of 167), 79.3% (96 of 121), 83.3% (50 of 60),
and 100% (17 of 17), respectively. Many of the adverse events
that occurred more frequently in the presence of hepatic
impairment were well-recognized symptoms of malaria.
Adverse events in children. One or more adverse events
were reported in 970 (72.8%) of 1,332 children; pyrexia
(28.6%) and cough (22.7%) occurred most frequently (Table 6).
Adverse events potentially related to hypersensitivity reactions occurred in 4.2% of children; the most frequent reactions
were rash (2.9%) and dermatitis (0.4%), which showed an

incidence of 1.1% during days 0–3 of treatment and 1.0%
during days 4–10 of treatment (Table 7). Nervous system
disorders were reported as adverse events in 193 patients
(14.5%), of which headache (n = 168, 12.6%), dizziness (n = 56,
4.2%), and clonus (n = 11, 0.8%) occurred in > 0.5% of patients.
All but one case of clonus were reported at a single center
during protocol-specified routine neurologic examinations in
which pre-defined signs and symptoms were evaluated, and
all cases were graded mild. No reports of clonus occurred in
the population of 899 children in the B2303 study. Ear and
labyrinth disorders occurred in 6 patients (0.5%), comprising
ear pain (n = 3), and cerumen impaction, ear pruritus, and
otorrhea in one patient each. Prolonged QT interval by
electrocardiogram ECG was reported in one child (0.1%); no

Table 4
Subpopulation analysis of 28-day PCR-corrected parasitologic cure rate (evaluable population) for patients treated with artemether-lumefantrine
for uncomplicated Plasmodium falciparum malaria *
Characteristic

Age
> 1 month–≤ 2 years
2 years–≤ 12 years
12–≤ 16 years
Body weight (kg)
5–< 10
10–< 15
15–< 25
25–< 35
≥ 35
Body weight (kg)
< 70
≥ 70
Baseline parasite density, no. (%)†
≤ 100,000/μL
> 100,000/μL
Renal function,‡ no. (%)
Normal
Mild dysfunction
Moderate dysfunction
Severe dysfunction
Missing
Hepatic function,§ no. (%)
Normal
Mild dysfunction
Moderate dysfunction
Severe dysfunction
Missing¶

Adults (all patients), no./total (%)

Adults (Study A2401), no./total (%)

Children, no./total (%)

–
–
–

–
–
–

366/377 (97.1)
374/384 (97.4)
52/53 (98.1)

–
–
–
–
–

–
–
–
–
–

210/217 (96.8)
283/290 (97.6)
198/204 (97.1)
50/51 (98.0)
50/51 (98.0)

–
–

52/52 (100.0)
66/71 (93.0)

–
–

399/408 (97.8)
27/28 (96.4)

50/50 (100.0)
0/0

718/737 (97.4)
74/77 (96.1)

182/188 (96.8)
118/126 (93.7)
9/9 (100.0)
0/0
186/187 (99.5)

87/91 (95.6)
27/28 (96.4)
0/0
0/0
5/5 (100.0)

169/173 (97.7)
289/302 (95.7)
174/176 (98.9)
85/86 (98.8)
75/77 (97.4)

146/147 (99.3)
101/106 (95.3)
45/48 (93.8)
9/13 (69.2)
194/196 (99.0)

57/58 (98.3)
33/35 (94.3)
16/17 (94.1)
0/0
13/14 (92.9)

137/141 (97.2)
159/164 (97.0)
21/22 (95.5)
1/2 (50.0)
474/485 (97.7)

* PCR = polymerase chain reaction. PCR analysis was not performed in study A2401.
† Data on baseline parasite count not available in parasites/microliter for all patients.
‡ According to creatinine clearance (Cockcroft-Gault/Shull): normal, > 80 mL/minute; mild dysfunction, ≥ 50–≤ 80 mL/minute; moderate dysfunction, ≥ 30–< 50 mL/minute; severe dysfunction,
< 30 mL/minute.
§ Defined as normal, either total bilirubin ≤ upper limit of normal (ULN), and aspartate aminotransferase (AST) ≤ ULN or total bilirubin ≤ ULN and AST value missing; mild dysfunction, either
total bilirubin ≤ ULN and AST > ULN, or total bilirubin > ULN – 1.5 × ULN regardless of AST value; moderate dysfunction, total bilirubin > 1.5 – 3 × ULN regardless of AST value; severe dysfunction, total bilirubin > 3 × ULN regardless of AST value; missing, baseline for total bilirubin is missing regardless of whether AST value is missing. If baseline AST value was missing, baseline alanine
aminotransferase value was used as per the criteria for AST.
¶ Total bilirubin value was missing.
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Children (n = 1,332), no. (%)

Any
Headache
Anorexia
Dizziness
Asthenia
Arthralgia
Myalgia
Nausea
Pyrexia
Chills
Sleep disorder
Palpitations
Vomiting
Abdominal pain
Fatigue
Hepatomegaly
Splenomegaly
Diarrhea
Cough
Anemia
P. falciparum infections

557 (86.1)
360 (55.6)
260 (40.2)
253 (39.1)
243 (37.6)
219 (33.8)
206 (31.8)
169 (26.1)
159 (24.6)
147 (22.7)
144 (22.3)
115 (17.8)
113 (17.5)
112 (17.3)
111 (17.2)
59 (9.1)
57 (8.8)
46 (7.1)
37 (5.7)
23 (3.6)
13 (2.0)

970 (72.8)
168 (12.6)
175 (13.1)
56 (4.2)
63 (4.7)
39 (2.9)
39 (2.9)
61 (4.6)
381 (28.6)
72 (5.4)
27 (2.0)
24 (1.8)
242 (18.2)
112 (8.4)
46 (3.5)
75 (5.6)
124 (9.3)
100 (7.5)
302 (22.7)
115 (8.6)
224 (16.8)

56 (4.2)
38 (2.9)
2 (0.2)
1 (0.1)
5 (0.4)
2 (0.2)
2 (0.2)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)

Total (n = 1,332)
> 28 (n = 910)

11 (1.2)
6 (0.7)
0
0
2 (0.2)
0
0
0
1 (0.1)
1 (0.1)
0
1 (0.1)
0
0
20 (1.6)
13 (1.0)
0
0
4 (0.3)
1 (0.1)
1 (0.1)
1 (0.1)
0
0
1 (0.1)
0
0
0

11–28 (n = 1,280)

Children, no. (%)

4–10 (n = 1,306)

13 (1.0)
9 (0.7)
1 (0.1)
1 (0.1)
0
1 (0.1)
0
0
0
0
0
0
1 (0.1)
0
14 (1.1)
11 (0.8)
1 (0.1)
0
0
0
1 (0.1)
0
0
0
0
0
0
1 (0.1)
26 (4.0)
21 (3.2)
4 (0.6)
1 (0.2)
0
0
0
0
0
0
0
0
0
0
1 (0.4)
1 (0.4)
0
0
0
0
0
0
0
0
0
0
0
0
2 (0.3)
2 (0.3)
0
0
0
0
0
0
0
0
0
0
0
0
6 (1.0)
3 (0.5)
2 (0.3)
1 (0.2)
0
0
0
0
0
0
0
0
0
0

Adults (n = 647), no. (%)

18 (2.8)
16 (2.5)
2 (0.3)
0
0
0
0
0
0
0
0
0
0
0

Adverse event

Any event
Rash
Urticaria
Face edema
Dermatitis
Eczema
Pustular rash
Allergic conjunctivitis
Atopic dermatitis
Infected dermatitis
Hypersensitivity
Oropharyngeal blistering
Maculo-papular rash
Face swelling

Table 6
Adverse events in ≥ 5% of adults or children (safety population) treated
with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria

1–3 (n = 1,332)

other adverse events potentially related to QT prolongation
were recorded.
Four (0.3%) children died. Deaths were caused by severe
P. falciparum infection on day 28 (new infection or recrudescence was undetermined) in a patient who was parasite free
≤ 24 hours and still parasite free on day 13; gastroenteritis on
day 8 with diarrhea treated with oral rehydration therapy; an
unspecified infection with pyrexia and dehydration treated
with quinine, paracetamol, metoclopramide, and amoxicillin;
and hemorrhage on day 5 after scarification by a traditional
healer; all deaths were considered unrelated to AL by investigators. Thirty serious adverse events were reported by investigators in 17 patients (1.3%), including P. falciparum infection
(7), convulsion (3), pyrexia (2), and anemia (2). None of the
three cases of convulsion was considered to be related to
AL; each was reported together with malaria or pyrexia, and
may have represented febrile convulsions. All other serious
adverse events were reported in no more than one patient.

Total (n = 647)

* mITT = modified intent-to teat; CI = confidence interval. The time at which parasite clearance and fever clearance were assessed varied between studies.
† Kaplan Meier estimates; if the last observation is censored, the mean is underestimated.

> 28 (n = 224)

45/877 (5.1%)
90/869 (10.4%)
14/828 (1.7%)
8/846 (0.9%)

Adults, no. (%)

7.9 (7.9–8.0)
25.2 ± 1.9

11–28 (n = 596)

35.3 (31.7–35.7)
33.2 ± 0.6
792 (90.3)
60 (6.8)
25 (2.9)

4–10 (n = 625)

Parasite clearance time (hours)
Median (95% CI)†
42.3 (41.5–43.2)
Mean ± SE†
47.3 ± 1.6
≤ 48 hours, no. (%)
471 (78.6)
> 48 hours, no. (%)
102 (17.0)
Not achieved, no. (%)
26 (4.3)
Fever clearance time (hours)
Median (95% CI)†
28.5 (22.3–34.0)
Mean ± SE†
37.4 ± 1.8
Gametocytes, no. (%)
Baseline
58/596 (9.7%)
> 0–72 hours
90/597 (15.1%)
> 72 hours–day 7
42/543 (7.7%)
> Day 7
23/554 (4.2%)

Children (n = 877)

0–3 (n = 647)

Adults (n = 599)

Adverse event

Endpoint

Days, preferred term

Table 5
Secondary efficacy endpoints (mITT population) for patients treated
with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria*

Table 7
Adverse events potentially related to hypersensitivity reactions occurring in > 1 adult or > 1 child, according to time after start of artemether-lumefantrine treatment (day 0) (safety population) for
uncomplicated Plasmodium falciparum malaria
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One serious adverse event was reported as having a suspected
relationship with AL. This event was a case of urticarial rash
in a four-year-old patient that resolved ≤ 5 days after antihistamine treatment.
Seventy-one children (5.3%) left the study prematurely
because of adverse events. Seventy of these 71 children were
enrolled in study B2303, in which the protocol specified that
any patient who required a second replacement dose of study
drug was to be removed from the study. Four patients stopped
treatment because of an adverse event other than vomiting.
These events were P. falciparum infection plus anemia in one
patient, P. falciparum infection plus iron deficiency anemia
in another patient, a lower respiratory tract infection in one
patient, and urticaria in one patient as described above.
Pediatric patients with mild, moderate, or severe renal
impairment at baseline had more adverse events than those
without renal impairment (69.4%, 354 of 510; 77.4%, 226 of
292; and 92.2%, 94 of 102 versus 60.7%, 198 of 326). Children
with mild or moderate hepatic impairment had a higher incidence of adverse events than those with normal function
(77.6%, 132 of 170 and 91.7%, 22 of 24 versus 65.3%, 94 of
144, respectively) but numbers of patients with moderate (n =
24) or severe (n = 2) hepatic impairment were low.
Laboratory parameters. Hematogic parameters improved
during follow-up, which is consistent with resolution of acute
malaria. Mean values ± SD for hemoglobin level, leukocyte
count, neutrophil count, and platelet count at baseline were
12.3 ± 2.5 g/dL, 6.1 ± 2.4 × 109/L, 3.9 ± 1.9 × 109/L, and 130
± 75 × 109/L, respectively, in adults, and 9.3 ± 1.7 g/dL, 9.3 ±
3.8 × 109/L, 4.8 ± 2.8 × 109/L, and 181 ± 99 ×109/L in children.
At days 26–39, the corresponding values were 12.8 ± 1.7 g/dL,
7.4 ± 2.2 ×109/L, 3.9 ± 1.7 × 109/L, and 231 ± 81 × 109/L in adults
and 10.4 ± 1.4 g/dL, 9.1 ± 3.3 × 109/L, 3.5 ± 1.9 × 109/L, and
310 ± 130 × 109/L in children. Renal function (assessed by
creatinine clearance) increased from baseline and liver
function values (AST, alanine aminotransferase, and bilirubin)
decreased from baseline, which is consistent with malaria and
its resolution. Hemolysis-related adverse events were not
reported in adults. Four potential hemolysis-related adverse
events occurred in the pediatric population (0.3%), all of
which were increased reticulocyte counts.
DISCUSSION
In this pooled analysis, the largest of its type so far to
assess AL therapy for the treatment of acute uncomplicated
P. falciparum malaria, AL achieved high cure rates and rapid
symptom relief in adults and children and a good safety and
tolerability profile. The efficacy of AL was similar for patients
of all ages in malaria-endemic regions. In the only study of
travelers from non-endemic regions, analysis was complicated
by poor follow-up rates, but efficacy of AL also appeared to be
excellent in the per protocol population.36 In addition, gametocyte carriage decreased markedly from baseline after AL
administration, which suggested that use of AL can contribute
to reducing malaria transmission.
The observed day 28 PCR-corrected cure rate in evaluable patients was approximately 97% in adults and children,
which exceeded the recommendation of WHO that antimalarial drugs should show a cure rate of 95%.1 The cure rate was
largely unaffected by age, body weight, baseline parasite count,
or kidney function. A trend to lower cure rates in patients with
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poor baseline liver function may have been an artifact of small
patient numbers and/or reflect the development of hepatic
impairment in patients with more severe malaria. Efficacy was
maintained in the youngest children, who showed a cure rate
in evaluable children 1 month–2 years of age of approximately
97%. Importantly, the cure rate was similar in all body weight
groups in children, despite the difference in doses received on
a milligram per kilogram basis within each dosing category.
Recent reports that showed decreased rates of parasite
clearance after treatment with artesunate and ACTs in western Cambodia are of concern.43,44 However, if one considers
this dataset and other recent studies, there is no convincing
evidence that the efficacy of AL has changed in recent years.45
The seven studies included in our analysis spanned the period
1996–2007, but most adults received AL treatment during
1996–1999, and the largest studies in children took place during
2002–2007. Randomized, multicenter trials during 2005–2009 in
Africa10,11,14,20,22,23,28,46,47 and Asia24,25,48 have each demonstrated a
PCR-corrected cure rate greater than 95% after AL treatment
in a variety of populations and settings. These studies have not
included Cambodia, and it is likely that alterations in artemisinin sensitivity that have led to changes in parasite clearance in
that country are not yet relevant in most malarious areas. In
addition, an advantage of the AL combination is that lumefantrine has never been used as monotherapy for the treatment of
malaria,1 and resistance to this drug in field isolates has not yet
clearly been demonstrated.
Parasite and fever clearance were achieved rapidly after
treatment with AL in adult and pediatric populations. The
slower fever clearance observed in study A2401 may have
been caused by less frequent evaluation in this study and the
relatively small proportion of patients (approximately 20%)
who used antipyretics compared with other trials (approximately 80% in studies A025, A026, and A028).
The reduction in gametocytemia after treatment with AL is
noteworthy. Clearance of gametocytes, the parasite form that
infects mosquitoes, breaks the cycle of transmission, and thus
contributes to malaria control. Artemisinins have gametocytocidal properties and reduce gametocyte carriage,4 and AL
has shown significantly greater gametocytocidal activity than
antimalarial drugs other than artemisinin.16,27,49–51 Randomized
trials have demonstrated significantly lower rates of gametocytemia after AL treatment compared with oral quinine47 or
dihydroartemisinin-piperaquine50,52 in patients in Africa with
uncomplicated P. falciparum malaria. In our analysis, the proportion of patients with gametocytemia after day 7 decreased
by more than 50% from baseline in adults and by approximately 80% in children. Less than 1% of treated children were
positive for gametocytes after day 7.
Our analysis showed no unexpected safety concerns in
almost 2,000 patients treated with AL. These results are consistent with those of other studies that demonstrated excellent
safety and tolerability of AL.11,28,53,54 Most of the frequently
reported adverse events were typical signs and symptoms of
malaria.55 There were few serious adverse events or deaths,
and serious adverse events were only rarely suspected to be
related to AL therapy. Urticaria was reported as a severe
adverse event in only one child and in no adults. Most adverse
events related to the nervous system, ear, and labyrinth disorders were transient and reversible, and there were no adverse
events associated with QTc prolongation. Hemolysis-related
adverse events were absent in adults and rare in the pediatric
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population (reticulocyte count increase in 0.3% of patients,
in parallel with an increase in hemoglobin level) with the few
reported events deemed unrelated to AL treatment. Thus, AL
treatment does not appear to trigger hemolysis, consistent with
the findings reported by Premji and others56 in a randomized,
double-blind trial of patients in Africa with uncomplicated P.
falciparum malaria.
Unforeseen differences were not observed in the adverse
event profile or laboratory results between subgroups. The
higher rate of adverse events reported in patients with hepatic
or renal impairment is likely to reflect more severe malaria
in these groups. Cough was more frequent in children than in
adults, which is not unexpected because respiratory infections
are common in children in Africa with malaria.57 Previous
reports have suggested that cough is unlikely to be causally
related to artemesinin-based therapy, and the fact that time to
onset of cough was relatively evenly distributed throughout
the duration of the studies suggests that cough was probably
not related either to malaria or to AL treatment. The higher
rates of headache and dizziness in older children compared
with young children and infants were probably caused by
increased ability to report symptoms.
This pooled analysis had some limitations. First, as an
unplanned pooling of data, the seven studies used various
schedules for assessment and procedures for reporting adverse
events. Accordingly, the reported rates of events cannot reliably be compared between trials. However, it is unlikely that
this limitation impaired detection of any novel safety signals.
Second, three of the seven studies were undertaken before
2000, i.e., more than 10 years ago, although there is no evidence
to suggest that the efficacy and safety of AL have changed in
the past decade45 because there are numerous more recent randomized trials confirming its therapeutic effect.10,11,14,20,22–25,28,46–48
Third, five studies were open-label and two were single-arm
studies. The open-label designs were used because of the difficulty of using double-blind methods, which would have
required large numbers of tablets in these acutely ill patients.
Some studies were non-comparative, either because no suitable comparator was available at the time or because inclusion of a control arm would have greatly increased the time
required for recruitment. Perhaps less importantly, but still of
relevance, supervision of the AL doses was not specified for
two trials. Fourth, no adult patients were recruited in Africa,
but the studies in children were predominantly in African children. However, there is no evidence in the literature of a difference in PCR-corrected AL cure rates between geographic
regions.60 Fifth, no children were included in the only study of
non-immune persons. Sixth, laboratory data collection was relatively limited and varied between studies, and sampling and
analysis were often restricted by local facilities. Sixth, because
studies were derived from the Novartis database to permit full
access to data, it must be remembered that all trials were supported by Novartis as part of the registration activity for AL in
the United States, Europe, Switzerland, and malaria-endemic
countries.
In conclusion, in this pooled analysis of almost 2,000
patients, the PCR-corrected 28-day cure rate for AL treatment of uncomplicated P. falciparum malaria exceeded 95%
in adults and children, and showed a good safety and tolerability profile and rapid reduction in gametocytemia. Although
data for non-immune persons remain limited, our findings
are consistent with the recommendation that AL be used as

first-line treatment of uncomplicated P. falciparum malaria in
patients of all ages, whether they are semi-immune residents
or non-immune visitors in malaria endemic or non-endemic
regions.
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